Otsuka's PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
Source: SeekingAlpha
2025-07-16 14:25:11 ET
More on Otsuka Holdings, H. Lundbeck A/S
- Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers
- Vera plunges as Otsuka outperforms with IgA nephropathy therapy
- Seeking Alpha’s Quant Rating on Otsuka Holdings
- Historical earnings data for Otsuka Holdings
- Dividend scorecard for Otsuka Holdings
Read the full article on Seeking Alpha
For further details see:
Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
Otsuka Holdings Co. Ltd.
NASDAQ: OTSKF
OTSKF Trading
0.0% G/L:
$67.105 Last:
107 Volume:
$67.105 Open:
OTSKF Latest News
May 17, 2025 01:00:00 am
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
February 06, 2025 02:00:00 pm
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
